NCT04232722 (HCC) is a Phase 2 clinical trial of Arsenicals in HCC, sponsored by Zhejiang University.

Who is sponsoring NCT04232722?

NCT04232722 is sponsored by Zhejiang University.

What drugs are being tested in NCT04232722?

Interventions in NCT04232722: Arsenicals.

Is NCT04232722 still recruiting?

NCT04232722 is currently status unknown. Last updated 18 January 2020.

Last reviewed 2020-01-18 · How we verify

NCT04232722: HCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation

Status unknown Phase 2 Last updated 18 January 2020

What this trial tests

Phase 2 trial testing Arsenicals in HCC in 43 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
31 December 2021

30 June 2022

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	1 January 2020
Primary completion	31 December 2021
Estimated completion	30 June 2022
Sites	1 location across China

Drugs / interventions tested

Arsenicals — full drug profile →

Conditions studied

HCC — all drugs for HCC →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with HCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To analyze the safety, efficacy and pharmacokinetic characteristics of sorafenib combined with compound huangdai tablets in patients with recurrent hepatocellular carcinoma after liver transplantation

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies.
Mossenta M, Busato D, Dal Bo M, Toffoli G. · · 2020 · cited 60× · PMID 32585931 · DOI 10.3390/cancers12061668
Systemic Treatment for Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Mazzarelli C, Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group, Berardi F, Bonfichi A, et al · · 2026 · PMID 41892169 · DOI 10.3390/curroncol33030141

Verify or expand the search:

Other recruiting trials for HCC

Currently open trials in the same condition.

NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
NCT07300488 — Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma · Phase 2, PHASE3 · active not recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07099274 — Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f · Phase 2 · recruiting
NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04232722 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 18 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04232722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing